Neugebauer, Monica E.
Hsu, Alvin http://orcid.org/0000-0003-4034-2788
Arbab, Mandana
Krasnow, Nicholas A. http://orcid.org/0000-0002-4131-1855
McElroy, Amber N. http://orcid.org/0000-0002-4169-0015
Pandey, Smriti
Doman, Jordan L.
Huang, Tony P. http://orcid.org/0000-0003-2904-830X
Raguram, Aditya
Banskota, Samagya
Newby, Gregory A. http://orcid.org/0000-0001-7869-2615
Tolar, Jakub
Osborn, Mark J.
Liu, David R. http://orcid.org/0000-0002-9943-7557
Funding for this research was provided by:
Howard Hughes Medical Institute (Liu investigatorship)
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (R01EB027793, R01EB031172)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (U01AI142756)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM118062)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1HG009490)
Article History
Received: 14 June 2022
Accepted: 28 September 2022
First Online: 10 November 2022
Competing interests
: M.E.N. and D.R.L have filed patent applications on this work. D.R.L. is a consultant for Prime Medicine, Beam Therapeutics, Pairwise Plants, Chroma Medicine, Resonance Medicine and Nvelop Therapeutics, companies that use genome editing, epigenome engineering or PACE, and owns equity in these companies. M.J.O. receives compensation as a consultant for Agathos Biologics. The remaining authors declare no competing interests. Correspondence: drliu@fas.harvard.edu.